Morita M, Murase T, Okumura Y, et al. - This study intended to present the clinicopathological significance of EGFR pathway gene mutations and CTRC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma. Researchers studied for CTRC1/3-MAML2 fusions and gene changes in the EGFR, RAS family (KRAS, HRAS, and NRAS), PIK3CA, BRAF, and AKT1 in 101 MEC cases. They also investigated mutations in TP53. In 62.4% of the cases, CTRC1/3-MAML2 fusions were observed. They distinguished KRAS, HRAS, and PIK3CA mutations in 6.9%, 2.0%, and 6.9%, respectively, but other EGFR pathway genes were not mutated. In MEC individuals, RAS/PIK3CA mutations were frequently identified and may be a biomarker for poorer prognosis. In most of the young MEC individuals, CTRC1/3-MAML2 fusions were positive.